News
-
May. 28, 2026EnPlusOne Biosciences Welcomes Biotech Veteran, Jim Weissman, to Board of Directors
-
May. 13, 2026
TIDES 2026 Presentation: “Pushing the Efficiency and Scale of Enzymatic RNA Synthesis”
-
May. 12, 2026
EnPlusOne Biosciences Highlights Significant Advancements to its ezRNA™ Enzymatic RNA Synthesis Platform and Introduces Novel Modifications for Next-Generation RNA Therapeutics
-
May. 06, 2026
CEO Clare Murray, Ph.D. Discusses EnPlusOne’s ezRNA Platform on Biotech TV
-
Oct. 21, 2025
Breakout Ventures 2025 Annual Meeting, Presentation by Clare Murray
-
May. 15, 2025
EnPlusOne Biosciences To Present New Data at TIDES USA
-
Apr. 25, 2025
EnPlusOne Biosciences Appoints Clare Murray, Ph.D. as CEO
-
Feb. 27, 2025EnPlusOne Raises $10m in Financing
-
Aug. 15, 2024EnPlusOne Biosciences to Collaborate with Wyss Institute on Up to $27 Million Agreement By ARPA-H to Develop Disease-Agnostic Immunotherapeutic RNA Platform
-
Aug. 13, 2024Nature Biotechnology publishes pivotal EnPlusOne paper on Template-Independent Enzymatic Synthesis of RNA Oligonucleotides